-
1 Comment
Jagsonpal Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 82.0% above its 200 day moving average.
From a valuation standpoint, the stock is 74.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.
Jagsonpal Pharmaceuticals Limited's total revenue rose by 35.9% to $571M since the same quarter in the previous year.
Its net income has increased by 137.8% to $54M since the same quarter in the previous year.
Finally, its free cash flow grew by 297.1% to $170M since the same quarter in the previous year.
Based on the above factors, Jagsonpal Pharmaceuticals Limited gets an overall score of 5/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | INE048B01035 |
| Dividend Yield | 0.8% |
|---|---|
| Beta | 0.42 |
| Market Cap | 15B |
| PE Ratio | 26.52 |
| Target Price | None |
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. It serves health care professionals and government institutions. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for JAGSNPHARM.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
